

Supplemental Table 3: Treatment Emergent Adverse Events Attributed to Either Doxorubicin, Pembrolizumab, or Both, Any Grade

	N	%
<i>At Least One Treatment-Related Adverse Event</i>	30	100.0%
Nausea	23	76.7%
Fatigue	17	56.7%
Neutrophil Count Decreased	14	46.7%
Vomiting	13	43.3%
Diarrhea	12	40.0%
White Blood Cell Decreased	12	40.0%
Alopecia	11	36.7%
Anemia	10	33.3%
Mucositis Oral	9	30.0%
Arthralgia	6	20.0%
Febrile Neutropenia	5	16.7%
Hypothyroidism	5	16.7%
Lymphocyte Count Decreased	4	13.3%
Platelet Count Decreased	4	13.3%
Generalized Muscle Weakness	4	13.3%
Chills	3	10.0%
Constipation	3	10.0%
Dehydration	3	10.0%
Dry Mouth	3	10.0%
Dysgeusia	3	10.0%
Hyperthyroidism	3	10.0%
Pain in Extremity	3	10.0%
Skin and Subcutaneous Tissue Disorders - Other	3	10.0%
Abdominal Pain	2	6.7%
Alkaline Phosphatase Increased	2	6.7%
Anorexia	2	6.7%
Arthritis	2	6.7%
Colitis	2	6.7%
Cough	2	6.7%
Creatinine Increased	2	6.7%
Dry Skin	2	6.7%
Fever	2	6.7%
Hypokalemia	2	6.7%
Hyponatremia	2	6.7%
Hypotension	2	6.7%
Lipase Increased	2	6.7%
Malaise	2	6.7%
Musculoskeletal and Connective Tissue Disorder - Other	2	6.7%
Myalgia	2	6.7%
Oral Pain	2	6.7%

Serum Amylase Increased	2	6.7%
Sore Throat	2	6.7%
Watering Eyes	2	6.7%
Lung Infection	2	6.7%
Autoimmune Disorder	2	6.7%
Alanine Aminotransferase Increased	1	3.3%
Aspartate Aminotransferase Increased	1	3.3%
Back Pain	1	3.3%
Blood Bilirubin Increased	1	3.3%
Bone Pain	1	3.3%
Bruising	1	3.3%
Cardiac Disorders - Other	1	3.3%
Confusion	1	3.3%
Dizziness	1	3.3%
Dysphagia	1	3.3%
Flank Pain	1	3.3%
Gastritis	1	3.3%
Gastrointestinal Disorders - Other	1	3.3%
Hemorrhoids	1	3.3%
Hirsutism	1	3.3%
Hyperglycemia	1	3.3%
Hypomagnesemia	1	3.3%
Infections and Infestations - Other	1	3.3%
Insomnia	1	3.3%
Menorrhagia	1	3.3%
Nail Discoloration	1	3.3%
Pancreatitis	1	3.3%
Presyncope	1	3.3%
Pruritus	1	3.3%
Rectal Pain	1	3.3%
Skin Hyperpigmentation	1	3.3%
Skin Infection	1	3.3%
Stomach Pain	1	3.3%
Urinary Incontinence	1	3.3%
Weight Loss	1	3.3%
Wound Infection	1	3.3%
Edema Limbs	1	3.3%
Ejection Fraction Decreased	1	3.3%
Palmar-Plantar Erythrodysesthesia Syndrome	1	3.3%
Non-Cardiac Chest Pain	1	3.3%
Gastroesophageal Reflux Disease	1	3.3%